08:13 AM EDT, 06/21/2024 (MT Newswires) -- Clene ( CLNN ) said Friday that preliminary data showed its lead drug candidate CNM-Au8 as a potential treatment for Rett Syndrome, a rare neurologic disorder that causes developmental impairments.

The development of CNM-Au8 has been focused on treating amyotrophic lateral sclerosis and multiple sclerosis, but it is now being considered for Rett Syndrome after showing statistical significance in enhancing neuroprotective effects needed to treat the disease, Clene ( CLNN ) said.

CNM-Au8 is an oral catalytic nanotherapeutic that targets energy metabolism to enhance neuronal survival and function, according to the company.

Shares of the company were down 2.9% in recent Friday premarket activity.

Price: 0.3800, Change: -0.01, Percent Change: -2.86